Locations:
Search IconSearch
April 10, 2018/Neurosciences

PACNS or RCVS? Differences in Imaging and Test Results

Why precise diagnosis matters

By Rula Hajj-Ali, MD, and Leonard Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

An extensive workup is required to rule out primary angiitis of the central nervous system (PACNS), a devastating disease in which exclusive inflammation and destruction of vessels in the CNS cause progressive, debilitating neurological deficits. Prognosis improves greatly with proper treatment, but with nonspecific tests and many confounding mimics, diagnosis can be tricky.

One of PACNS’s closest mimics is reversible cerebral vasoconstriction syndrome (RCVS). Distinguishing between RCVS and PACNS is critical because the treatment protocol is so vastly different. Misdiagnosing PACNS as RCVS can deprive a patient of medications that prolong survival and improve outcomes. We offer a brief overview of differences in the results of diagnostic tests below. See this post for differences in clinical presentation. A future post will focus on management.

Diagnostic test results

Cerebrospinal fluid (CSF) analysis is essential in the differentiation between PACNS and RCVS and in excluding infections and malignancies. PACNS cases will show lymphocyte-predominant pleocytosis, elevated protein levels and normal glucose levels. In RCVS, normal CSF is the rule, unless the CSF is contaminated by subarachnoid or parenchymal hemorrhages.

Neuroimaging in PACNS cases is always abnormal. Ischemic infarctions are the most common lesions and are often multiple and bilateral. Nonspecific high-intensity lesions are also common in PACNS as visualized on T2-weighted magnetic resonance imaging (MRI) with a fluid-attenuated recovery sequence. RCVS is usually but not always abnormal on neuroimaging. Upon initial presentation, 20 percent of patients may have normal neuroimaging. Edema is a common finding, and computed tomography can show convexity subarachnoid hemorrhage or intracranial hemorrhage, both more common in RCVS.

Advertisement

Cerebrovascular imaging is always abnormal in RCVS and usually abnormal in PACNS. Stenosis and dilation visualized by direct or indirect angiography are not specific to either condition. Involvement of vascular beds in RCVS is usually bilateral and affecting multiple territories which may not be true in PACNS. Further, the cerebrovascular abnormalities in RCVS are dynamic and improve over time.

In the lab, both PACNS and RCVS will test normal for C-reactive protein, erythrocyte sedimentation rate, complete blood count and complete metabolic profile. Serologic tests for rheumatologic, autoinflammatory, autoimmune, malignant and infectious diseases are negative in PACNS and RCVS.

Advances in neuroimaging such as the use of 3-Tesla high resolution MRI specifically to assess the vessel wall hold promise in differentiating between both entities. The vessel walls in RCVS do not show enhancement while in PACNS enhancement occurs.

A note on the gold standard

Brain biopsy is the often-feared, underutilized gold standard in the diagnosis of PACNS. An open-wedge procedure is considered low risk, and an experienced neurosurgeon working as part of a multidisciplinary team can perform a biopsy with greater than 80 percent sensitivity and 90-100 percent specificity. Finding inflammation in the vessel wall is characteristic of PACNS, while brain biopsies are normal in RCVS.

Dr. Hajj-Ali is Associate Director of the Center for Vasculitis Care and Research in the Department of Rheumatic and Immunologic Diseases. Dr. Calabrese is Director of the R.J. Fasenmyer Center for Clinical Immunology.

Advertisement

Advertisement

Related Articles

older man at a table with younger man handing him pill containers
October 15, 2025/Neurosciences/Brain Health
Real-World Data Suggest Two Antidiabetic Drug Classes May Curb Alzheimer’s Risk

Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors

Two people working in a community garden
Rehabilitation: Beyond Recovery, Toward Renewed Participation

Tasked-based therapy improves social connection and quality of life

gloved hand holding blood vial with neuropathology slide in background
October 10, 2025/Neurosciences/Epilepsy
Blood-Based Epigenetic Biomarkers Differentiate Focal Cortical Dysplasia Subtypes

Paired blood and brain tissue methylation findings raise prospect of noninvasive precision diagnosis

young man using walking canes on a city street
Vidofludimus for Progressive MS: No Impact on Brain Atrophy but Hints of a Role for Disability

Mixed results from phase 2 CALLIPER trial of novel dual-action compound

illustration of myelin sheaths wrapped around neuron axons
Revised McDonald Criteria for Multiple Sclerosis: A Big Step Toward Biomarker-Driven Diagnosis

A co-author of the new recommendations shares the updates you need to know

Dr. Jason Savage against a decorative background with podcast button overlay
October 2, 2025/Neurosciences/Podcast
Essentials of Revision Spine Deformity Surgery (Podcast)

Success for these complex operations requires judicious patient selection and presurgical patient optimization

physician talking with a patient in medical office
De-Escalation of Disease-Modifying Therapies in MS: A Real-World Look at Outcomes

Rebound risk is shaped by patient characteristics and mechanism of action of current DMT

woman speaking to a doctor
Tool Shows Promise for Individualized Decision Support on Stopping Disease-Modifying Therapy for Multiple Sclerosis

First-of-kind prediction model demonstrates high consistency across internal and external validation

Ad